{"entity":{"id":"immunotherapy","kind":"section","name":"Immunotherapy","aka":[],"tldr":"Immunotherapy helps the patient's own immune system recognise and destroy the cancer.","summary":"This section gathers the treatments that work by getting the patient's own immune system to recognise and destroy the cancer rather than attacking the tumour directly with a drug. It covers checkpoint inhibitors against PD-1, PD-L1, CTLA-4 and LAG-3, bispecific T-cell engagers, cancer vaccines including personalised mRNA neoantigen vaccines, oncolytic viruses, cytokines and innate-immune agonists. Two problems dominate: working out in advance who will respond, and converting cold tumours into hot ones. Technology entries filed here include Monoclonal antibodies, Bispecific antibodies, Immuno-PET and Intravesical therapy, and companies placed in the section include Incyte, ImmunityBio, CG Oncology, Ferring Pharmaceuticals, Y-mAbs Therapeutics and Shanghai Henlius Biotech.","asOf":"2026-09-04","links":[{"label":"NCI: Immunotherapy to treat cancer","url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-immunotherapy","journal-of-immunotherapy","oncoimmunology"],"dependsOn":[],"notes":[],"order":9,"icon":"shield"},"route":"/fronts/immunotherapy/","neighbours":{"journal":[{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/"},{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","route":"/journals/journal-of-immunotherapy/"},{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/"}],"company":[{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/"},{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/"},{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/"},{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"},{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/"},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"},{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/"},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"},{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","route":"/companies/amgen-ventures/"},{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/"},{"id":"anocca","kind":"company","name":"Anocca","route":"/companies/anocca/"},{"id":"aop-health","kind":"company","name":"AOP Health","route":"/companies/aop-health/"},{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/"},{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","route":"/companies/asher-bio/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/"},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"},{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/"},{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"},{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/"},{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","route":"/companies/catalent/"},{"id":"celldex","kind":"company","name":"Celldex Therapeutics","route":"/companies/celldex/"},{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/"},{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","route":"/companies/checkpoint-therapeutics/"},{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/"},{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/"},{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/"},{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/"},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/"},{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/"},{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/"},{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/"},{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/"},{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/"},{"id":"eris-biotech","kind":"company","name":"Eris Biotech","route":"/companies/eris-biotech/"},{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/"},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/"},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/"},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/"},{"id":"gamgee","kind":"company","name":"Gamgee","route":"/companies/gamgee/"},{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/"},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/"},{"id":"granza-bio","kind":"company","name":"Granza Bio","route":"/companies/granza-bio/"},{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/"},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"},{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/"},{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/"},{"id":"humane-genomics","kind":"company","name":"Humane Genomics","route":"/companies/humane-genomics/"},{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/"},{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"},{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/"},{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/"},{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/"},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"},{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/"},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/"},{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/"},{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/"},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/"},{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","route":"/companies/kernal-biologics/"},{"id":"kopra-bio","kind":"company","name":"Kopra Bio","route":"/companies/kopra-bio/"},{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/"},{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/"},{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"},{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/"},{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/"},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/"},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/"},{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/"},{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/"},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/"},{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/"},{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/"},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/"},{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","route":"/companies/persephone-biosciences/"},{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"},{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"},{"id":"serova","kind":"company","name":"Serova","route":"/companies/serova/"},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"},{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/"},{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"},{"id":"sotio","kind":"company","name":"SOTIO Biotech","route":"/companies/sotio/"},{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","route":"/companies/strand-therapeutics/"},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"},{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","route":"/companies/sun-pharma/"},{"id":"synsorybio","kind":"company","name":"SynsoryBio","route":"/companies/synsorybio/"},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"},{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/"},{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"},{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/"},{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/"},{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/"},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/"},{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/"},{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/"},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/"},{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/"}],"technology":[{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/"},{"id":"bacterial-vector-vaccines","kind":"technology","name":"Bacterial vector cancer vaccines","route":"/technologies/bacterial-vector-vaccines/"},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/"},{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/"},{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/"},{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/"},{"id":"cd40-agonists","kind":"technology","name":"CD40 agonist antibodies","route":"/technologies/cd40-agonists/"},{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/"},{"id":"chronotherapy","kind":"technology","name":"Chronotherapy: timing treatment to the body clock","route":"/technologies/chronotherapy/"},{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"},{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/"},{"id":"dietary-fibre-microbiome-io","kind":"technology","name":"Dietary fibre and the gut microbiome for immunotherapy response","route":"/technologies/dietary-fibre-microbiome-io/"},{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/"},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/"},{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/"},{"id":"histotripsy-immune-priming","kind":"technology","name":"Histotripsy as an immune primer","route":"/technologies/histotripsy-immune-priming/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"rejuv-recovery-endocrine-permanence","kind":"technology","name":"Immune endocrine damage is usually permanent, and almost nobody is told","route":"/technologies/rejuv-recovery-endocrine-permanence/"},{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"immunocytokines","kind":"technology","name":"Immunocytokines (antibody-cytokine fusions)","route":"/technologies/immunocytokines/"},{"id":"in-situ-vaccination","kind":"technology","name":"In situ vaccination","route":"/technologies/in-situ-vaccination/"},{"id":"il12-electroporation","kind":"technology","name":"Intratumoural gene electrotransfer (IL-12 plasmid)","route":"/technologies/il12-electroporation/"},{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/"},{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/"},{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/"},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"},{"id":"nk-cell-engagers","kind":"technology","name":"NK cell engagers","route":"/technologies/nk-cell-engagers/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/"},{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/"},{"id":"probiotics-antibiotic-stewardship-io","kind":"technology","name":"Probiotics, antibiotics and stewardship around immunotherapy","route":"/technologies/probiotics-antibiotic-stewardship-io/"},{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/"},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/"},{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/"},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/"},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/"},{"id":"tim3-blockade","kind":"technology","name":"TIM-3 blockade","route":"/technologies/tim3-blockade/"},{"id":"trained-innate-immunity","kind":"technology","name":"Trained innate immunity","route":"/technologies/trained-innate-immunity/"},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"},{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/"},{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/"},{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"paper":[{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/"},{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/"},{"id":"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","kind":"paper","name":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","route":"/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/"},{"id":"paper-bischoff-onyx-015-science-1996","kind":"paper","name":"Bischoff 1996: the adenovirus that was said to replicate only where p53 was lost","route":"/key-papers/paper-bischoff-onyx-015-science-1996/"},{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/"},{"id":"paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018","kind":"paper","name":"Bourgeois-Daigneault 2018: giving the virus before surgery, not after everything else has failed","route":"/key-papers/paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018/"},{"id":"paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025","kind":"paper","name":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","route":"/key-papers/paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025/"},{"id":"paper-coffey-reovirus-ras-science-1998","kind":"paper","name":"Coffey 1998: reovirus grows in cells with an activated Ras pathway, which describes a great many cancers","route":"/key-papers/paper-coffey-reovirus-ras-science-1998/"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/"},{"id":"paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017","kind":"paper","name":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","route":"/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/"},{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/"},{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/"},{"id":"paper-hietanen-rigvir-echovirus-viruses-2022","kind":"paper","name":"Hietanen 2022: the marketed oncolytic virus Rigvir was no more oncolytic than any other echovirus isolate","route":"/key-papers/paper-hietanen-rigvir-echovirus-viruses-2022/"},{"id":"paper-wong-ignyte-rp1-nivolumab-jco-2025","kind":"paper","name":"IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy","route":"/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/"},{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/"},{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/"},{"id":"paper-kelly-russell-oncolytic-history-moltherapy-2007","kind":"paper","name":"Kelly and Russell 2007: a century of trying to treat cancer with viruses, and why it kept stopping","route":"/key-papers/paper-kelly-russell-oncolytic-history-moltherapy-2007/"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/"},{"id":"paper-antonarakis-keynote-199-pembrolizumab-jco-2020","kind":"paper","name":"KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/"},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/"},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/"},{"id":"paper-leach-allison-ctla4-blockade-science-1996","kind":"paper","name":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","route":"/key-papers/paper-leach-allison-ctla4-blockade-science-1996/"},{"id":"paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017","kind":"paper","name":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","route":"/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/"},{"id":"paper-martuza-engineered-hsv-glioma-science-1991","kind":"paper","name":"Martuza 1991: the first genetically engineered virus built to treat a cancer","route":"/key-papers/paper-martuza-engineered-hsv-glioma-science-1991/"},{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/"},{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/"},{"id":"paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","kind":"paper","name":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","route":"/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/"},{"id":"paper-andtbacka-optim-talimogene-jco-2015","kind":"paper","name":"OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus","route":"/key-papers/paper-andtbacka-optim-talimogene-jco-2015/"},{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/"},{"id":"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","kind":"paper","name":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/"},{"id":"paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024","kind":"paper","name":"PHOCUS: an oncolytic vaccinia virus before sorafenib in liver cancer did worse than sorafenib alone","route":"/key-papers/paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024/"},{"id":"paper-pugh-self-experimentation-publication-jme-2026","kind":"paper","name":"Pugh 2026: should a journal publish a scientist's experiment on herself?","route":"/key-papers/paper-pugh-self-experimentation-publication-jme-2026/"},{"id":"paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017","kind":"paper","name":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","route":"/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/"},{"id":"paper-prima-rituximab-maintenance-follicular-lancet-2011","kind":"paper","name":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","route":"/key-papers/paper-prima-rituximab-maintenance-follicular-lancet-2011/"},{"id":"paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023","kind":"paper","name":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023/"},{"id":"paper-russell-mv-nis-myeloma-mayo-2014","kind":"paper","name":"Russell 2014: a measles virus given into the vein put one patient's myeloma into complete remission","route":"/key-papers/paper-russell-mv-nis-myeloma-mayo-2014/"},{"id":"paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012","kind":"paper","name":"Russell, Peng and Bell 2012: the field states its own problems","route":"/key-papers/paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012/"},{"id":"paper-elm-2-odronextamab-follicular-ann-oncol-2024","kind":"paper","name":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/"},{"id":"paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023","kind":"paper","name":"Shalhout 2023: what the approved oncolytic viruses actually do in practice","route":"/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/"},{"id":"paper-stojdl-vsv-interferon-defect-natmed-2000","kind":"paper","name":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","route":"/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/"},{"id":"paper-prima-final-rituximab-maintenance-follicular-jco-2019","kind":"paper","name":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","route":"/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/"},{"id":"paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","kind":"paper","name":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","route":"/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/"},{"id":"paper-halassy-self-experiment-ovt-vaccines-2024","kind":"paper","name":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","route":"/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/"},{"id":"paper-cloughesy-toca5-glioma-jamaoncol-2020","kind":"paper","name":"Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work","route":"/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/"},{"id":"paper-todo-g47delta-glioblastoma-natmed-2022","kind":"paper","name":"Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus","route":"/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/"},{"id":"paper-xia-h101-head-neck-aizheng-2004","kind":"paper","name":"Xia 2004: the randomised trial behind China's approval of the oncolytic adenovirus H101","route":"/key-papers/paper-xia-h101-head-neck-aizheng-2004/"}],"idea":[{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/"},{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/"},{"id":"idea-nl-diet-covariates-io-trials","kind":"idea","name":"Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial","route":"/ideas/idea-nl-diet-covariates-io-trials/"},{"id":"lymphoma-ev-fixed-duration-chemotherapy-free-first-line","kind":"idea","name":"Fixed-duration, chemotherapy-free first-line treatment for the indolent lymphomas","route":"/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/"},{"id":"idea-cost-subcutaneous-community","kind":"idea","name":"Give subcutaneous immunotherapy in community clinics and at home","route":"/ideas/idea-cost-subcutaneous-community/"},{"id":"idea-cost-extended-interval-default","kind":"idea","name":"Make six-weekly immunotherapy the default schedule","route":"/ideas/idea-cost-extended-interval-default/"},{"id":"lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","kind":"idea","name":"Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America","route":"/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/"},{"id":"idea-lung-small-cell-platform-with-shared-controls-and-subtypes","kind":"idea","name":"Run small-cell lung cancer as one platform with shared controls and subtype stratification","route":"/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/"},{"id":"idea-crc-mss-immunotherapy-by-biomarker-not-by-line","kind":"idea","name":"Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed","route":"/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/"},{"id":"idea-cost-vial-sharing-dose-rounding","kind":"idea","name":"Share vials and round doses to stop throwing away expensive drug","route":"/ideas/idea-cost-vial-sharing-dose-rounding/"},{"id":"idea-cost-low-dose-immunotherapy-trials","kind":"idea","name":"Test one-tenth-dose immunotherapy where the full dose is unaffordable","route":"/ideas/idea-cost-low-dose-immunotherapy-trials/"},{"id":"lymphoma-ev-the-drugs-that-cure-and-the-places-without-them","kind":"idea","name":"The drugs that cure lymphoma, and the places that do not have them","route":"/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/"}],"person":[{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","route":"/people/daniel-ludwig/"},{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/"},{"id":"gary-middleton","kind":"person","name":"Gary Middleton","route":"/people/gary-middleton/"},{"id":"herbert-irving","kind":"person","name":"Herbert Irving","route":"/people/herbert-irving/"},{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/"},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/"},{"id":"leon-black","kind":"person","name":"Leon Black","route":"/people/leon-black/"},{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","route":"/people/michael-bloomberg/"},{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/"},{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/"},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/"},{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","route":"/people/sidney-kimmel/"},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/"},{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/"},{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/"}],"trial":[{"id":"flyer","kind":"trial","name":"FLYER","route":"/trials/flyer/"},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/"},{"id":"fortplus","kind":"trial","name":"FORTplus","route":"/trials/fortplus/"},{"id":"goya","kind":"trial","name":"GOYA","route":"/trials/goya/"},{"id":"ielsg-19","kind":"trial","name":"IELSG-19","route":"/trials/ielsg-19/"},{"id":"lyma","kind":"trial","name":"LyMa","route":"/trials/lyma/"},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/"},{"id":"mosun-lbt-fl","kind":"trial","name":"Mosunetuzumab against rituximab in low tumour burden follicular lymphoma","route":"/trials/mosun-lbt-fl/"},{"id":"mosun-len-mzl","kind":"trial","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","route":"/trials/mosun-len-mzl/"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/"},{"id":"remarc","kind":"trial","name":"REMARC","route":"/trials/remarc/"},{"id":"rosewood","kind":"trial","name":"ROSEWOOD","route":"/trials/rosewood/"}],"term":[{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/"},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/"},{"id":"immune-endocrinopathy","kind":"term","name":"Immune-related endocrinopathies (thyroiditis, hypophysitis)","route":"/terms/immune-endocrinopathy/"},{"id":"myocarditis","kind":"term","name":"Immune-related myocarditis","route":"/terms/myocarditis/"},{"id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/"},{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/"},{"id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/"},{"id":"mss-pmmr","kind":"term","name":"Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)","route":"/terms/mss-pmmr/"},{"id":"pd-l1-testing","kind":"term","name":"PD-L1 expression testing (22C3, SP142, SP263)","route":"/terms/pd-l1-testing/"},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/"},{"id":"step-up-dosing","kind":"term","name":"Step-up dosing (T-cell engagers)","route":"/terms/step-up-dosing/"},{"id":"stk11-keap1","kind":"term","name":"STK11 / KEAP1 co-mutations","route":"/terms/stk11-keap1/"},{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/"}],"institution":[{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/"},{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/"},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/"},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/"},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/"},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/"},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/"},{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/"},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/"},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/"},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/"},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/"},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/"},{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/"},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/"},{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/"},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/"},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/"},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/"},{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","route":"/institutions/ludwig-cancer-research/"},{"id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/"},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/"},{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/"},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/"},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/"},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/"},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/"},{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/"},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/"},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/"},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/"},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/"},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/"},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/"},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/"},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/"},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/"}]}}